Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of...
Saved in:
| Superior document: | Frontiers Research Topics |
|---|---|
| : | |
| Year of Publication: | 2018 |
| Language: | English |
| Series: | Frontiers Research Topics
|
| Physical Description: | 1 electronic resource (385 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993548047404498 |
|---|---|
| ctrlnum |
(CKB)4920000000094130 (oapen)https://directory.doabooks.org/handle/20.500.12854/58773 (EXLCZ)994920000000094130 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Stefano Morotti auth Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond Frontiers Media SA 2018 1 electronic resource (385 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague. English cardiotoxicity cardiac electrophysiology. drug-induced arrhythmia QT interval prolongation multi-scale modeling 2-88945-539-4 Eleonora Grandi auth Esther Pueyo auth Blanca Rodriguez auth |
| language |
English |
| format |
eBook |
| author |
Stefano Morotti |
| spellingShingle |
Stefano Morotti Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond Frontiers Research Topics |
| author_facet |
Stefano Morotti Eleonora Grandi Esther Pueyo Blanca Rodriguez |
| author_variant |
s m sm |
| author2 |
Eleonora Grandi Esther Pueyo Blanca Rodriguez |
| author2_variant |
e g eg e p ep b r br |
| author_sort |
Stefano Morotti |
| title |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_full |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_fullStr |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_full_unstemmed |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_auth |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_new |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_sort |
safety pharmacology - risk assessment qt interval prolongation and beyond |
| series |
Frontiers Research Topics |
| series2 |
Frontiers Research Topics |
| publisher |
Frontiers Media SA |
| publishDate |
2018 |
| physical |
1 electronic resource (385 p.) |
| isbn |
2-88945-539-4 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT stefanomorotti safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT eleonoragrandi safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT estherpueyo safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT blancarodriguez safetypharmacologyriskassessmentqtintervalprolongationandbeyond |
| status_str |
n |
| ids_txt_mv |
(CKB)4920000000094130 (oapen)https://directory.doabooks.org/handle/20.500.12854/58773 (EXLCZ)994920000000094130 |
| carrierType_str_mv |
cr |
| hierarchy_parent_title |
Frontiers Research Topics |
| is_hierarchy_title |
Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| container_title |
Frontiers Research Topics |
| author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
| _version_ |
1796652178175164416 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01902nam-a2200361z--4500</leader><controlfield tag="001">993548047404498</controlfield><controlfield tag="005">20231214132846.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094130</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/58773</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094130</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stefano Morotti</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (385 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiac electrophysiology.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-induced arrhythmia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">QT interval prolongation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multi-scale modeling</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-539-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eleonora Grandi</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Esther Pueyo</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blanca Rodriguez</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:34:19 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338756800004498&Force_direct=true</subfield><subfield code="Z">5338756800004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338756800004498</subfield></datafield></record></collection> |